K
KOTAI Biotechnologies
High-throughput structural modeling and analysis for immune cell sequences
About KOTAI Biotechnologies
KOTAI Biotechnologies, Inc. specializes in immuno-informatics, leveraging artificial intelligence and big data analysis to develop next-generation therapeutics. The company collaborates with researchers and medical professionals to create personalized cancer immunotherapies using regenerated T cells derived from induced pluripotent stem (iPS) cells. Additionally, KOTAI Biotechnologies participates in clinical research on COVID-19, analyzing the immune profiles of patients to contribute to the global understanding and treatment of the disease. The company operates in the biotechnology sector, primarily serving researchers, medical professionals, and healthcare institutions. Its business model revolves around providing advanced data analysis services and collaborative research opportunities, generating revenue through service fees and research grants.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Suita-Shi, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Osaka University Venture Capital
Series B and later3 investors entered at this stage
Nissay Capital
Nippon Venture Capital
Senshu Ikeda Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KOTAI Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KOTAI Biotechnologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.